The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
== Litigation science == "Litigation science" describes analysis or data developed or produced expressly for use in a trial versus those produced in the course of independent research. This distinction was made by the U.S. 9th Circuit Court of Appeals when evaluating the admissibility of experts. This uses demonstrative evidence, which is evidence created in preparation of trial by attorneys or paralegals.
The end result will thus be multiple organ failure [10] and damage to the muscles and nerves in the arms and legs. The animal trials done before the clinical trial had failed to predict this extreme species-selective toxicity. This is mainly due to that humans have the human equilibrate nucleoside transporter-1 (hENT-1) which will allow selective uptake of FIAU into the mitochondria in a way that other species do not.
There have been proposals for reactors that consume nuclear waste and transmute it to other, less-harmful or shorter-lived, nuclear waste. In particular, the integral fast reactor was a proposed nuclear reactor with a nuclear fuel cycle that produced no transuranic waste and, in fact, could consume transuranic waste. It proceeded as far as large-scale tests but was eventually canceled by the U.S. Government. Another approach, considered safer but requiring more development, is to dedicate subcritical reactors to the transmutation of the left-over transuranic elements. An isotope that is found in nuclear waste and that represents a concern in terms of proliferation is Pu-239. The large stock of plutonium is a result of its production inside uranium-fueled reactors and of the reprocessing of weapons-grade plutonium during the weapons program. An option for getting rid of this plutonium is to use it as a fuel in a traditional light-water reactors (LWR). Several fuel types with differing plutonium destruction efficiencies are under study. Transmutation was banned in the United States in April 1977 by U. S. President Carter due to the danger of plutonium proliferation, but President Reagan rescinded the ban in 1981. Due to economic losses and risks, the construction of reprocessing plants during this time did not resume. Due to high energy demand, work on the method has continued in the European Union (EU). This has resulted in a practical nuclear research reactor called Myrrha in which transmutation is possible.
Blocking LRP5 expression using siRNA against LRP5 resulted in a significant decrease in MMP13 mRNA and protein expressions. The catabolic role of LRP5 appears to be mediated by the Wnt/beta-catenin pathway in human osteoarthritis. The polyphenol curcumin increases the mRNA expression of LRP5.
Sources: en.wikipedia.org
He was so dismayed that he began to have dye samples exposed to the sun to check for light-fastness. He then employed a Scottish chemist named John Christie to synthesize dyes based on the chemical structures that were more stable to sunlight, and began to market the dyes in his products as fast dyes, or sundour, which can translate to "hard to move" in Scots. Synthetic dyes were now produced in Britain, Germany, France, the US, Switzerland, Russia, the Austrian Empire, the Netherlands, Belgium, and Italy. At the end of this period, this grew to include Rumania (one firm), Greece (one firm), and Canada (two firms). The scale of the chemical plants also grew, for instance the Bayer company in 1907 had a reactor to make azo dye with a capacity of 20,000 liters. From 1900 to the first World War German firms controlled around 75% of the dye market. The concentration of chemical producers in Germany was perturbed by World War I, however, and the chemical industry of the United States of America in particular expanded rapidly, although Germany always remained a major player.
== Nomenclature note == Confusingly, there are two nomenclatures for FPR receptors and their genes, the first one used, FPR, FPR1, and FPR2 and its replacement (which corresponds directly to these three respective receptors and their genes), FPR1, FPR2, and FPR3. The latter nomenclature is recommended by the International Union of Basic and Clinical Pharmacology and is used here. Other previously used names for FPR1 are NFPR, and FMLPR; for FPR2 are FPRH1, FPRL1, RFP, LXA4R, ALXR, FPR2/ALX, HM63, FMLPX, and FPR2A; and for FPR3 are FPRH2, FPRL2, and FMLPY.
==== Circulatory system ==== The network of blood vessels include the great vessels (comprising large elastic arteries and large veins), other arteries (which carry blood away from the heart) and veins (which carry blood to the heart), smaller arterioles, and capillaries, which join with venules. Blood is a fluid consisting of plasma (comprising serum and clotting factors), red blood cells, white blood cells, and platelets. Components of the blood include nutrients (such as proteins and minerals), hemoglobin, hormones, and gases such as oxygen and carbon dioxide. These substances provide nourishment, help the immune system to fight diseases, and help maintain homeostasis through mechanisms such as thermoregulation, osmoregulation, and acid-base regulation. The circulatory system has two divisions, a systemic circuit (i.e. the left heart pumping oxygenated blood to the rest of the body (via the aorta) and into the right heart (via the venae cava)) and a pulmonary circuit (i.e. the right heart pumping deoxygenated blood to the lungs (via the pulmonary artery) and into the left heart (via the pulmonary vein)). In the human heart:
A 2023 systematic review and meta-analysis of 75 studies, covering 55,761 men across data collected between 1942 and 2021, found that average erect penis length increased by approximately 24% over the past 29 years globally, across all age groups and geographic regions. The authors noted that this rapid rate of change, too fast to be explained by genetic drift alone, points toward environmental or lifestyle factors as likely contributors. They drew a parallel with concurrent trends in male reproductive health, including declining sperm counts and testosterone levels and rising rates of genital birth defects such as hypospadias, which have similarly been attributed to environmental exposures. Specific hypothesized mechanisms include increased prenatal and postnatal exposure to endocrine-disrupting chemicals, as well as earlier onset of puberty, itself potentially linked to sedentary lifestyles or hormonal disruption.
== Premise == It takes place after a 1980 plane crash claims America's Olympic boxing team. It shows a determined coach taking on the monumental task of assembling and training new fighters for glory at the 1984 Summer Olympics.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.